Navigating Complex Patients With Parkinson’s Disease Psychosis (CME/CE Patient Simulation)
Activity Description and Purpose
Psychosis is an often-challenging complication of Parkinson’s disease. Neurologist Dr Daniel Claassen and Psychiatrist Dr Gregory Pontone will take you through an interactive patient simulation, sharing their approaches to the management of a more complex patient. You will follow this patient over the course of a few years as her disease progresses and decide on the optimal paths to take in making her diagnosis and recommending treatment. You will learn about the latest guidelines and evidence underlying current best practice.
This educational activity is intended for neurologists, psychiatrists, and primary care clinicians caring for patients with PDP.
After completing this activity, participants will be better able to:
- Integrate routine screening for symptoms of psychosis in patients with PD into practice
- Develop individualized, evidence-based care plans for persons with PDP
|Daniel Claassen, MD, MS|
Associate Professor of Neurology
Chief, Behavioral and Cognitive Neurology Division
Director, Cognition and Movement Laboratories
Vanderbilt University Medical Center
Gregory Pontone, MD, MHS
MedEdicus LLC adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to accreditation of the activity.
Daniel Claassen, MD, is a consultant for Alterity Therapeutics and Spark Therapeutics, Inc; and is a contracted researcher for Alterity Therapeutics and, CHDI Foundation, Inc, F. Hoffman-La Roche Ltd, Genentech, Inc, Prilenia Therapeutics, and Vaccinex Inc.
Gregory Pontone, MD, MHS, is a consultant for ACADIA Pharmaceuticals Inc and Cerevance.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco, or ACADIA Pharmaceuticals Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.2
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation